Novartis (NVS) agreed to sell the U.S. rights to bladder medicine Enablex for $400 million.
Ireland-based Warner Chilcott will take over the marketing, sales and manufacturing of the drug in the United States, Novartis said in a statement. The deal is expected to close by the end of October.
Sponsored Links
Novartis may also receive “milestone payments” of as much as $20 million.
In 2005, Novartis…
Continue reading Novartis Sells U.S. Rights to Enablex for $400 Million
Novartis Sells U.S. Rights to Enablex for $400 Million originally appeared on DailyFinance on Fri, 24 Sep 2010 06:46:00.
Filed Under: Company News, Health Care, Novartis, Insurance, Retail